Liquid biopsy and glioblastoma

• Published in: Exploration of targeted anti-tumor therapy Vol. 4; no. 1; pp. 28 - 41
• Main Authors: Eibl, Robert H, Schneemann, Markus
• Format: Journal Article
• Language: English
• Published: United States Open Exploration 2023; Open Exploration Publishing Inc
• Subjects: cell-free dna; circulating tumor cells; circulating tumor dna; glioblastoma; liquid biopsy; minimal residual disease; monitoring; Review; treatment response; glioblastoma; treatment response; cell-free DNA; Liquid biopsy; minimal residual disease; circulating tumor cells; monitoring; circulating tumor DNA
• ISSN: 2692-3114; 2692-3114
• DOI: 10.37349/etat.2023.00121

Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on neuroimaging techniques followed by histopathological and molecular analysis of resected or biopsied tissue. A recent paradigm shift in diagnostics ranks the molecular analysis of tissue samples as the new gold standard over classical histopathology, thus correlating better with the biological behavior of glioblastoma and clinical prediction, especially when a tumor lacks the typical hallmarks for glioblastoma. Liquid biopsy aims to detect and quantify tumor-derived content, such as nucleic acids (DNA/RNA), circulating tumor cells (CTCs), or extracellular vesicles (EVs) in biofluids, mainly blood, cerebrospinal fluid (CSF), or urine. Liquid biopsy has the potential to overcome the limitations of both neuroimaging and tissue-based methods to identify early recurrence and to differentiate tumor progression from pseudoprogression, without the risks of repeated surgical biopsies. This review highlights the origins and time-frame of liquid biopsy in glioblastoma and points to recent developments, limitations, and challenges of adding liquid biopsy to support the clinical management of glioblastoma patients.